D-Index & Metrics Best Publications
Research.com 2022 Best Female Scientist Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 108 Citations 52,754 691 World Ranking 2666 National Ranking 1559
Best female scientists D-index 108 Citations 53,418 945 World Ranking 594 National Ranking 368

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Female Scientist Award

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

Hope S. Rugo mainly investigates Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. Her work focuses on many connections between Internal medicine and other disciplines, such as Surgery, that overlap with her field of interest in Gastroenterology. Her research in Oncology intersects with topics in Trastuzumab, Chemotherapy, Phases of clinical research, Carboplatin and Hazard ratio.

Her Breast cancer research is multidisciplinary, relying on both Everolimus and Progression-free survival. Her research investigates the connection between Cancer and topics such as Physical therapy that intersect with issues in Psychological intervention. The Metastatic breast cancer study combines topics in areas such as Taxane, Capecitabine, Hormone receptor, Disease and Bevacizumab.

Her most cited work include:

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (2040 citations)
  • Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy (1201 citations)
  • Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer (1190 citations)

What are the main themes of her work throughout her whole career to date?

Hope S. Rugo mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. Internal medicine connects with themes related to Surgery in her study. Hope S. Rugo has included themes like Taxane, Phases of clinical research, Hormone receptor, Letrozole and Clinical endpoint in her Oncology study.

She combines subjects such as Bevacizumab, Clinical trial, Adverse effect, Gynecology and Stage with her study of Breast cancer. She studied Metastatic breast cancer and Vinorelbine that intersect with Gemcitabine and Eribulin. Hope S. Rugo has researched Chemotherapy in several fields, including Gastroenterology and Randomized controlled trial.

She most often published in these fields:

  • Internal medicine (73.05%)
  • Oncology (60.84%)
  • Breast cancer (54.00%)

What were the highlights of her more recent work (between 2019-2021)?

  • Internal medicine (73.05%)
  • Oncology (60.84%)
  • Breast cancer (54.00%)

In recent papers she was focusing on the following fields of study:

Her primary areas of investigation include Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. The Chemotherapy, Triple-negative breast cancer, Hazard ratio and Adverse effect research Hope S. Rugo does as part of her general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science. Her Oncology research also works with subjects such as

  • Pembrolizumab, which have a strong connection to Carboplatin and Randomized controlled trial,
  • Palbociclib which connect with Letrozole.

Neutropenia is closely connected to Gastroenterology in her research, which is encompassed under the umbrella topic of Breast cancer. Her studies in Cancer integrate themes in fields like Cancer research and Talazoparib. Her research integrates issues of Taxane, Regimen, Progressive disease and Capecitabine in her study of Metastatic breast cancer.

Between 2019 and 2021, her most popular works were:

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology (367 citations)
  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial (299 citations)
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. (136 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Breast cancer

Her primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. Internal medicine is frequently linked to Placebo in her study. Her studies in Oncology integrate themes in fields like Pembrolizumab, Gemcitabine, Trastuzumab and Palbociclib.

She focuses mostly in the field of Breast cancer, narrowing it down to matters related to Gastroenterology and, in some cases, Clinical endpoint. Her work in the fields of Cancer, such as Fulvestrant and Aromatase inhibitor, intersects with other areas such as Cyclin-dependent kinase 4. Her Chemotherapy study incorporates themes from Talazoparib, Veliparib, Olaparib and PARP inhibitor.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga;Mario Campone;Martine Piccart;Howard A. Burris.
The New England Journal of Medicine (2012)

2777 Citations

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Kathy D. Miller;Linnea I. Chap;Frankie A. Holmes;Melody A. Cobleigh.
Journal of Clinical Oncology (2005)

1624 Citations

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones.
The New England Journal of Medicine (2016)

1472 Citations

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

David G. DeNardo;David G. DeNardo;Donal J. Brennan;Elton Rexhepaj;Brian Ruffell.
Cancer Discovery (2011)

1449 Citations

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Kimberly L. Blackwell;Harold J. Burstein;Anna Maria Storniolo;Hope Rugo.
Journal of Clinical Oncology (2010)

1106 Citations

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

F. Cardoso;A. Costa;E. Senkus;M. Aapro.
Annals of Oncology (2017)

879 Citations

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris;Hope S. Rugo;Svetislava J. Vukelja;Charles L. Vogel.
Journal of Clinical Oncology (2011)

814 Citations

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Jennifer K. Litton;Hope S. Rugo;Johannes Ettl;Sara A. Hurvitz.
The New England Journal of Medicine (2018)

808 Citations

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett.
The Lancet (2017)

774 Citations

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

José Baselga;Vladimir Semiglazov;Peter van Dam;Alexey Manikhas.
Journal of Clinical Oncology (2009)

753 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Hope S. Rugo

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 137

Javier Cortes

Javier Cortes

Vall d'Hebron Hospital Universitari

Publications: 116

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 115

Fabrice Andre

Fabrice Andre

Institut Gustave Roussy

Publications: 104

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 100

Sherene Loi

Sherene Loi

Peter MacCallum Cancer Centre

Publications: 89

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 86

Laura J. Esserman

Laura J. Esserman

University of California, San Francisco

Publications: 84

Nan Lin

Nan Lin

Harvard University

Publications: 79

Mario Campone

Mario Campone

Inserm : Institut national de la santé et de la recherche médicale

Publications: 79

José Baselga

José Baselga

Memorial Sloan Kettering Cancer Center

Publications: 77

Fatima Cardoso

Fatima Cardoso

Champalimaud Foundation

Publications: 76

Peter A. Fasching

Peter A. Fasching

University of Erlangen-Nuremberg

Publications: 76

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 72

Pierfranco Conte

Pierfranco Conte

University of Padua

Publications: 72

Sibylle Loibl

Sibylle Loibl

Goethe University Frankfurt

Publications: 69

Trending Scientists

Pierre Comon

Pierre Comon

Grenoble Alpes University

Ibrahim Aljarah

Ibrahim Aljarah

University of Jordan

Sung Ho Moon

Sung Ho Moon

Intel (United States)

Hichem Eleuch

Hichem Eleuch

University of Sharjah

Hiroshi Kominami

Hiroshi Kominami

Kindai University

Ingrid Milošev

Ingrid Milošev

Jožef Stefan Institute

Patrick Schultz

Patrick Schultz

University of Strasbourg

Chih-Lin Hsieh

Chih-Lin Hsieh

University of Southern California

Michael J. Angilletta

Michael J. Angilletta

Arizona State University

E. J. Threlfall

E. J. Threlfall

Government of the United Kingdom

Yong-hui Jiang

Yong-hui Jiang

Duke University

Wouter Peters

Wouter Peters

Wageningen University & Research

Robert B. Cook

Robert B. Cook

Oak Ridge National Laboratory

Craig H. Hart

Craig H. Hart

Brigham Young University

Jishnu Das

Jishnu Das

Georgetown University

Peter Goldreich

Peter Goldreich

California Institute of Technology

Something went wrong. Please try again later.